Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.
Sara Hurvitz, Matteo Simonelli, Ramón Yarza...
https://pubmed.ncbi.nlm.nih.gov/41108088/Actively Recruiting
Led by Boehringer Ingelheim · Updated on 2026-10-28
910
Participants Needed
104
Research Sites
N/A
Total Duration
Researchers are evaluating zongertinib, alone and combined with other treatments, for adults aged 18 and older who have various types of HER2-positive cancers that have spread and cannot be removed by surgery. This study focuses on patients whose tumors show HER2 abnormalities and who have not responded to prior treatments. The goal is to find a suitable dose of zongertinib that patients can tolerate well and to see if the treatment can shrink tumors. Participants receive treatment in cycles and are assigned to different groups. In Part 1, groups receive increasing doses of zongertinib combined with one of several other drugs, including trastuzumab deruxtecan, trastuzumab emtansine, trastuzumab with capecitabine, zanidatamab, or mFOLFOX6 chemotherapy. In Part 2, participants are randomly assigned to groups receiving different doses of zongertinib alone or with these treatments. Some groups also participate in an extension phase. The study is open-label and conducted at multiple centers. During the study, participants visit the study site regularly for tumor assessments using CT or MRI scans, health monitoring, and reporting of any side effects. Researchers track tumor size changes, dose-limiting toxicities within 21 days, and objective responses up to 50 months. Patient-reported outcomes and other safety and pharmacokinetic measurements are also collected. Participants remain under medical observation throughout the study, which may last several years.
CONDITIONS
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
B
Boehringer Ingelheim
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Boehringer Ingelheim
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational zongertinib combinations | Current HER2‑targeted regimens |
|---|---|---|
| What it is | Sequential investigational regimens combining zongertinib with HER2‑targeted agents such as trastuzumab emtansine, trastuzumab deruxtecan, trastuzumab, capecitabine, mFOLFOX6, zanidatamab or docetaxel in previously treated metastatic HER2‑positive cancers | Established HER2‑targeted combinations such as trastuzumab deruxtecan with pertuzumab in metastatic HER2‑positive breast cancer or trastuzumab plus chemotherapy in HER2‑positive gastric or gastroesophageal adenocarcinoma |
| Role in trial | This is the investigational intervention tested sequentially across multiple cohorts | These regimens represent current HER2‑targeted therapy approaches used outside the trial for context |
| Primary use | To test safety, dose optimization (Phase Ib) and anti‑tumor response (Phase II) of zongertinib combinations in metastatic HER2‑positive cancers | Used to treat metastatic HER2‑positive cancers according to current clinical guidelines |
| How it is given or performed | Oral zongertinib taken with intravenous or oral HER2‑targeted agents per cohort protocol | Administered as approved intravenous or oral regimens per standard practice |
| Evidence status | Efficacy being evaluated in early‑phase trial; response data not yet established | Efficacy established through randomized trials and included in current treatment guidelines |
| Important risks | Risks under evaluation; safety profile not fully characterized in combination cohorts | Known risks include toxicity such as interstitial lung disease and cardiotoxicity from HER2‑targeted agents |
| Important limitations | Sequential cohort design across heterogeneous combinations limits direct intra‑trial comparison and generalizability | Standard regimens may not be effective across all included cancer types, and resistance often develops |
| Patient impact | Not yet known; outcomes under investigation | Regimens are known to improve survival and response rates in metastatic HER2‑positive cancers |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Up to 21 days per dose evaluation period
Participants receive increasing doses of zongertinib alone or with other cancer treatments to find the highest dose they can tolerate.
Regular visits for safety and tumor assessments
Duration - Up to 50 months
Participants are randomly assigned to different groups receiving various doses of zongertinib alone or in combination with other treatments to evaluate response and safety over time.
Regular visits including imaging and health monitoring
Duration - Varies by participant
Some participants continue receiving treatment to further assess long-term safety and effectiveness.
Ongoing monitoring visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
19
Have more questions? Get in touch with our team for quick support
Sara Hurvitz, Matteo Simonelli, Ramón Yarza...
https://pubmed.ncbi.nlm.nih.gov/41108088/Boehringer Ingelheim
Lead Sponsor